BridgeMD
New treatment option for Gastric Lesion
Official title Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer
ClinicalTrials.gov ID: NCT05854368
What this study is testing
- What it's testing
- The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group. For this purpose: Patients with pre-existing gastric lesions will be invited to participate to this study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Common
- 18 years old or highter
- written informed consent prior to any study procedure
- Affiliated to a social insurance system Specific to patients with gastric lesions
- Untreated glandular atrophy (with or without intestinal metaplasia and/or dysplasia) and histologically diagnosed as of 2014
You likely can't join if
- Common
- Autoimmune disease or disease that impacts the immune system (e.g: HIV)
- Chronic inflammatory disease
- Known evolutive cancer (excluding gastric cancer)
- Treated in the last 3 months or currently treated with therapy that interferes with the immune system (e.g. immunosuppressive therapy)
- Current treatment with long-term corticosteroid therapy
See the full eligibility criteria
- Common
- 18 years old or highter
- written informed consent prior to any study procedure
- Affiliated to a social insurance system Specific to patients with gastric lesions
- Untreated glandular atrophy (with or without intestinal metaplasia and/or dysplasia) and histologically diagnosed as of 2014
- Treatment naïve Gastric cancer (distal or proximal adenocarcinoma)
- Common
- Autoimmune disease or disease that impacts the immune system (e.g: HIV)
- Chronic inflammatory disease
- Known evolutive cancer (excluding gastric cancer)
- Treated in the last 3 months or currently treated with therapy that interferes with the immune system (e.g. immunosuppressive therapy)
- Current treatment with long-term corticosteroid therapy
- Current treatment with long-term nonsteroidal anti-inflammatory drugs
- Pregnant woman or breastfeeding
- Patient or healthy volunteer under legal protection (e.g. guardianship)
- Patient or healthy volunteer currently participating to a clinical trial evaluating either an experimental medical product or a medical device
- Patient or healthy volunteer currently in custody Specific to Healthy Volunteer
- Known history of Helicobacter pylori infection
- Known history of gastric lesions (i.e. chronic gastritis, gastric atrophy, intestinal metaplasia, dysplasia and cancer)
The study team makes the final eligibility decision.
Where it's taking place
- Boulogne-Billancourt, France
- Clichy, France
- Le Kremlin-Bicêtre, France
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Boulogne-Billancourt, France; Clichy, France; Le Kremlin-Bicêtre, France; Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.